NCT03759522

Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: University of Alabama at Birmingham · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this study is to measure the concentration and the regional brain distribution of activated brain microglia/macrophages using the PET radiopharmaceutical \[F-18\]DPA-714 in individuals with chronic pain and fatigue suspected to be associated with neuroinflammation. The PET tracer \[F-18\]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia/macrophages and provides a non-invasive measure of neuroinflammation. The primary objective of this study is to determine if pain and fatigue patients have higher levels of neuroinflammation than HC individuals as measured with \[F-18\]DPA-714-PET/MRI.

Conditions

• Fibromyalgia
• Chronic Fatigue Syndrome
• Multiple Sclerosis
• Healthy

Interventions

Type	Name	Description
DRUG	DPA-714 PET/MRI	DPA-714 PET/MRI

Timeline

• Start date: 2019-02-03
• Primary completion: 2028-04-01
• Completion: 2028-04-01
• First posted: 2018-11-30
• Last updated: 2026-02-20

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study